CClinicalTrials.gg
CompletedNCT04699422Updated Dec 21, 2022

Serratus Anterior Plane Block Versus Standard of Care After Totally Endoscopic Aortic Valve Replacement

An interventional study of Serratus anterior plane block and PCIA with Piritramide in Analgesia, Surgery and Cardiac Disease, sponsored by Jessa Hospital. Completed at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-12-21.

Sponsored by Jessa Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The aim of this study is to assess and compare the efficacy of a serratus anterior plane (SAP) block and our current pain protocol (Patient Controlled Intravenous Analgesia with opioids) in the prevention and treatment of acute postoperative pain after totally endoscopic aortic valve replacement (AVR) surgery.

Read the detailed description

During the last two decades, cardiac surgical techniques changed dramatically. Evidence for good short and long-term outcome after endovascular and minimally invasive procedures is rising. The goal of avoiding sternotomy is earlier patient recovery without compromising safety. Therefore, enhanced recovery after surgery (ERAS) protocols have been implemented to aim for early extubation and ambulation. Analgesic regimens after cardiac surgery did not change significant however. Opioids remain the cornerstone of analgesia in the postoperative cardiac surgical care units, despite known side effects as nausea, constipation and risk for addiction. Neuraxial anesthetic techniques after cardiac surgery have been studied and validated to reduce opioid consumption. Their implementation in clinical practice however remains limited for two reasons. First, heparinization is required for cardiac surgery, which increases the risk neuraxial hematoma after neuraxial anesthesia, leading to deleterious complications as paraplegia. Secondly, neuraxial anesthesia induces orthosympathicolysis, enhancing vasoplegia after cardiac surgery. However, fascial plane blocks in cardiac surgery since peripheral blocks do not induce sympathicolysis and consequences of chest wall hematoma are limited.

In 2013, Blanco described the serratus anterior plane (SAP) block as an analgesic option for chest wall surgery. In this fascial plane block, local anesthetics are injected in the plane beneath the anterior serratus muscle and in the plane between latissimus dorsi and serratus anterior in an ultrasound guided manner. SAP block provides analgesia in dermatomes T2-T9. Recently, successful analgesia after SAP block has been demonstrated for soft tissue chest wall surgery, thoracotomy and rib fractures. No major side effects were reported. More specifically, no sympatholytic effects or chest wall hematoma were observed. However, up to now no prospective studies assessing the analgesic efficacy of SAP block after cardiac surgery are published. Two retrospective studies show conflicting results. Berthoud et al. retrospectively compared SAP block to continuous wound infusion after different types of minimally invasive cardiac surgery (MICS) and found reduced morphine consumption as well as shorter intensive care and hospital length of stay after SAP block. In contrast, Moll et al. found no difference in opioid consumption between SAP block and no block in patients after robotic coronary artery bypass grafting (rCABG). The authors comment they only performed the deep component of the SAP block, and some surgical entry points were outside dermatomes T2-T7.

Totally endoscopic aortic valve replacement (AVR) is a novel minimally invasive cardiosurgical technique. Surgical incision is made anteriorly in intercostal space two on the right hemithorax. Since intercostal space two is innervated by dermatomes T2-T3, somatic analgesia can be obtained with SAP block. In addition with a favorable safety profile and a minimal/non-existent risk of evoking sympatholytic effects, a SAP block may be a suitable analgesic technique to prevent/minimize postoperative pain after totally endoscopic AVR surgery.

02

Conditions studied

  • Analgesia
  • Surgery
  • Cardiac Disease

Browse trials for

03

In context

Heart Diseases

3,639 studies on the registry are indexed under Heart Diseases; 461 are open to participants now.

This study's enrollment of 80 is below the median of 100 across 1,779 interventional studies indexed under Heart Diseases.

Browse Heart Diseases studies →

Lead sponsor

Jessa Hospital is the lead sponsor of 85 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Scheduled for elective aortic valve replacement surgery via right anterolateral thoracotomy
  • Adult patients (minimally 18 years old)
  • EuroScore ii \< 3%
  • Bodyweight > 50 kg

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate
  • Inability to communicate due to language or neurologic barriers
  • Inability to control and self-administer opioids with PCIA or to comprehend the NRS pain score due to confusion or learning difficulties
  • Chronic use of opioids
  • Chronic use of analgesic antidepressants and/or antiepileptics
  • History of major trauma or surgery to right chest wall
  • History of chronic pain at right chest wall
  • Allergy to opioids and/or local anesthetics
  • Allergy to acetaminophen
  • Morbid obesity (BMI > 35)
  • Pregnancy
  • Peroperative events compromising early postoperative recovery (aortic dissection, systolic anterior motion of the mitral valve, cardiac tamponade, ..)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Active comparator
    Experimental group

    Patients in the experimental group will receive the serratus anterior plane block combined with postoperative PCIA with Piritramide.

    Procedure: Serratus anterior plane block · Drug: PCIA with Piritramide

  • Sham comparator
    Control group

    Patients in the control group will receive postoperative PCIA with Piritramide.

    Drug: PCIA with Piritramide

Interventions

  • ProcedureSerratus anterior plane block

    The needle will be introduced in-plane from supero-anterior to postero-inferior until the needle tip is positioned in the plane underneath the serratus muscle (deep compartment). Under continuous ultrasound guidance,30 cc Bupivacaine 0.25% will be injected in the deep compartment. After the deep component of the SAP is completed, the needle will be withdrawn to the subcutaneous tissues. The needle will be flattened and advanced in-plane to the plane superficial to the serratus muscles. 10 cc Bupivacaine 0.25% will be injected superficial to the serratus muscles after correct placement of the needle tip is confirmed on ultrasound

  • DrugPCIA with Piritramide

    A patient controlled intravenous analgesia system (IVAC PCAM®, Cardinal Health or CADD pump) with piritramide (Dipidolor®, Janssen) using following settings: bolus 2 mg and lockout interval 15 min.

    Also known as: PCIA with Dipidolor

06

What researchers measure

Primary outcomes

  1. Cumulative opioid consumption by patient-controlled intravenous analgesia (PCIA)

    Piritramide consumption (mg) will be directly read from the PCIA-system after 24 hours.

    Time frame: 24 hours after performing the SAP block

Secondary outcomes

  1. Opioid consumption during predetermined time intervals after surgery

    Piritramide consumption (mg) will be directly read from the PCIA-system at predetermined time intervals after performing the SAP block.

    Time frame: Every 4 hours until 24 hours after placement of the SAP block

  2. Opioid free patients first 24 postoperative hours

    Number of patients that do not require any opioids within the first 24 hours after surgery.

    Time frame: First 24 hours

  3. Opioid free patients during hospital length of stay

    Number of patients that do not require any opioids during the hospital length of stay

    Time frame: Through study completion, an average of 7 days

  4. Postoperative pain score in rest

    The postoperative pain on the surgical site is evaluated based on an 11-points numeric scale (Numerical Rating Sale - NRS) where 0 = no pain and 10 = worst pain ever.

    Time frame: 4, 8, 12, and 24 hours after performing the SAP block and at postoperative day 7.

  5. Quality of recovery after totally endoscopic aortic valve replacement

    Quality of recovery will be assessed via the 5-Dimensional European Quality of Life (EQ5D) and 36-Item Short Form Health Survey (SF-36) questionnaires concerning mobility, self care, daily activities and pain.

    Time frame: Postoperative days 2 and 7

  6. Overall patient satisfaction with analgesic therapy

    Overall patient satisfaction with analgesic therapy will be assessed with an 11-point Numeric Rating Scale (where 0 = not satisfied at all and 10 = extremely satisfied).

    Time frame: 24 hours after performing the serratus anterior plane block at postoperative day 1

  7. Postoperative nausea and vomiting (PONV)

    The simplified postoperative nausea and vomiting (PONV) impact scale will be used to assess PONV. The scale ranges from 0 to 6, where 0 means no nausea/vomiting. Clinically important PONV will be defined as a score of 5 or more.

    Time frame: 24 hours after performing the serratus anterior plane block at postoperative day 1

  8. Constipation

    Time to first defecation (postoperative days) or need for laxatives during hospital stay.

    Time frame: Until postoperative day 7

  9. Time to extubation

    Time from arrival to the ICU until extubation in minutes.

    Time frame: Throughout study completion, an average of 7 days

  10. ICU length of stay

    Time from arrival to the ICU until meeting discharge criteria to the ward in postoperative hours.

    Time frame: Until postoperative day 7

  11. Hospital length of stay

    Time to discharge out of the hospital in postoperative days (day of surgery = day 0)

    Time frame: Through study completion, an average of 7 days

  12. Pneumonia

    Defined as empirical antibiotic therapy for suspicion of pneumonia during hospital stay, in number of patients.

    Time frame: Until postoperative day 7

  13. Duration of vasopressor infusion

    Time from arrival to the ICU until full weaning from vasoactive substances (eg norepinephrine) in minutes. Patients not requiring any vasopressors will be excluded from this secondary outcome parameter.

    Time frame: Until postoperative day 7

  14. Subcutaneous emphysema

    Number of patients suffering subcutaneous emphysema. All patients will be investigated 24h after performing the SAP block (or control) by a blinded assessor.

    Time frame: 24 hours after performing the serratus anterior plane block at postoperative day 7

  15. Number of patients with new onset perioperative atrial fibrillation (POAF)

    Number of patients suffering witnessed (ECG recorded) POAF and patients with history of (paroxysmal) atrial fibrillation will not be taken into account for this secondary outcome parameter.

    Time frame: Until postoperative day 7

07

Study locations

1 site
  • Dr Bjorn Stessel
    Hasselt, 3500, Belgium
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04699422
Lead sponsor
Jessa Hospital
Responsible party
Stessel Björn (Principal Investigator, Jessa Hospital) — Principal investigator
First posted
Jan 7, 2021
Start date
Dec 3, 2020
Primary completion
Jul 4, 2022
Completion
Jul 4, 2022
Last update
Dec 21, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion